Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jacques Fontaine

Thoracic Surgery (Cardiothoracic Vascular Surgery) Tampa, FL Medical Doctor

NPI 1205028867 CMS profile 325968

12902 Magnolia Dr, Tampa, FL 33612

Open in the dashboard

General payments

$629,567

548 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$2,304 paid to institutions, not to them · program year 2019

Through program year 2025, Jacques Fontaine of Tampa, FL is reported in the CMS Open Payments database as having received $629,567 across 548 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $2,304 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Thoracic Surgery (Cardiothoracic Vascular Surgery) profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $109,483 92
2024 General $120,286 104
2023 General $118,435 85
2022 General $53,338 55
2021 General $93,214 85
2020 General $75,260 76
2019 General $59,551 51

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jacques Fontaine
  • Thoracic Surgery (Cardiothoracic Vascular Surgery) median
  • Middle half of Thoracic Surgery (Cardiothoracic Vascular Surgery)
  • National median

In program year 2025, general payments to Jacques Fontaine were reported at $109,483. Among 4,073 Thoracic Surgery (Cardiothoracic Vascular Surgery) profiles paid that year, the median was $791 and the middle half received between $208 and $3,074.

Show as a table
Year Jacques Fontaine Thoracic Surgery (Cardiothoracic Vascular Surgery) median Middle half National median
2019 $59,551 $886 $178–$3,167 $163
2020 $75,260 $341 $108–$1,605 $114
2021 $93,214 $453 $125–$1,886 $132
2022 $53,338 $695 $180–$2,566 $149
2023 $118,435 $745 $205–$2,662 $160
2024 $120,286 $799 $214–$2,967 $164
2025 $109,483 $791 $208–$3,074 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $169,967 140 payments
  2. Intuitive Surgical, Inc. $167,365 166 payments
  3. E.R. Squibb & Sons, L.L.C. $138,757 91 payments
  4. Davol Inc. $130,734 104 payments
  5. Baxter Healthcare $14,515 10 payments
  6. Medical Device Business Services, Inc. $3,183 3 payments
  7. Atricure, Inc. $1,264 5 payments
  8. Medtronic, Inc. $832 3 payments
  9. Biom'Up France SAS $518 5 payments
  10. Novocure Inc. $500 1 payment
  11. Other $1,931 20 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $261,294 81 payments
  2. Education $126,668 33 payments
  3. Honoraria $95,100 15 payments
  4. Travel and Lodging $73,551 207 payments
  5. Consulting Fee $53,617 23 payments
  6. Food and Beverage $19,338 189 payments
Products named General payments · program years 2019–2025
  1. Da Vinci Surgical System $160,365 161 payments
  2. OPDIVO $125,118 75 payments
  3. TAGRISSO $99,914 87 payments
  4. IMFINZI Oncology $17,812 15 payments
  5. IMFINZI Cardiovascular And Metabolism $17,457 19 payments
  6. COSEAL $10,671 3 payments
  7. HEMOPATCH $10,632 2 payments
  8. ARISTA $9,570 23 payments
  9. DA VINCI SP $7,000 5 payments
  10. ARISTA AH FlexiTip $5,035 14 payments
  11. Other $16,801 69 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

19

Median for Thoracic Surgery: 42

Drug cost

$53

Median for Thoracic Surgery: $318

Branded share of claims

0%

Median for Thoracic Surgery: 0%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Tramadol Hcl Generic 19 $53

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 910 Part D prescribers listed as Thoracic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 50 billing codes

Paid by Medicare

$101,100

Medicare's payments for the services billed

Medicare patients

109

Average age 73

Services billed

356

56 women, 53 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Cancer 75%
COPD 59%
Ischemic heart disease 53%
Arthritis 49%
Diabetes 29%
Chronic kidney disease 27%
Atrial fibrillation 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
OPDIVO
  • E.R. Squibb & Sons, L.L.C. $22,403
$22,403 — —
IMFINZI
  • AstraZeneca Pharmaceuticals LP $16,509
$16,509 — —
TAGRISSO
  • AstraZeneca Pharmaceuticals LP $5,663
$5,663 — —
TECENTRIQ
  • Genentech USA, Inc. $31
$31 — —
Alecensa
  • Genentech USA, Inc. $10
$10 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

548 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Thoracic Surgery (Cardiothoracic Vascular Surgery) in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record